BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 16128859)

  • 1. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
    Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
    Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients.
    Roman RM; Camargo PV; Borges FK; Rossini AP; Polanczyk CA
    Coron Artery Dis; 2010 May; 21(3):129-36. PubMed ID: 20305551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.
    Brown DL; Desai KK; Vakili BA; Nouneh C; Lee HM; Golub LM
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):733-8. PubMed ID: 14962945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline serum matrix metalloproteinase-9 level predicts long-term prognosis after coronary revascularizations in stable coronary artery disease.
    Ye ZX; Leu HB; Wu TC; Lin SJ; Chen JW
    Clin Biochem; 2008 Mar; 41(4-5):292-8. PubMed ID: 18067861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease.
    Blankenberg S; Rupprecht HJ; Poirier O; Bickel C; Smieja M; Hafner G; Meyer J; Cambien F; Tiret L;
    Circulation; 2003 Apr; 107(12):1579-85. PubMed ID: 12668489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction.
    Wang KF; Huang PH; Chiang CH; Hsu CY; Leu HB; Chen JW; Lin SJ
    Coron Artery Dis; 2013 Jan; 24(1):23-8. PubMed ID: 23151854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis.
    Heeschen C; Dimmeler S; Hamm CW; Fichtlscherer S; Simoons ML; Zeiher AM;
    J Am Coll Cardiol; 2005 Jan; 45(2):229-37. PubMed ID: 15653020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
    Huang PH; Lu TM; Wu TC; Lin FY; Chen YH; Chen JW; Lin SJ
    Coron Artery Dis; 2008 May; 19(3):187-93. PubMed ID: 18418236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy.
    Ohtsuka T; Nishimura K; Kurata A; Ogimoto A; Okayama H; Higaki J
    J Card Fail; 2007 Nov; 13(9):752-8. PubMed ID: 17996824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
    Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D
    Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level of high-sensitivity C-reactive protein in Saudi patients with chronic stable coronary artery disease.
    Habib SS
    J Ayub Med Coll Abbottabad; 2008; 20(2):3-6. PubMed ID: 19385446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparision of high sensitivity C-reactive protein and matrix metalloproteinase 9 in patients with unstable angina between with and without significant coronary artery plaques.
    Wang LX; Lü SZ; Zhang WJ; Song XT; Chen H; Zhang LJ
    Chin Med J (Engl); 2011 Jun; 124(11):1657-61. PubMed ID: 21740772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
    Bayes-Genis A; Conover CA; Overgaard MT; Bailey KR; Christiansen M; Holmes DR; Virmani R; Oxvig C; Schwartz RS
    N Engl J Med; 2001 Oct; 345(14):1022-9. PubMed ID: 11586954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease.
    Hlatky MA; Ashley E; Quertermous T; Boothroyd DB; Ridker P; Southwick A; Myers RM; Iribarren C; Fortmann SP; Go AS;
    Am Heart J; 2007 Dec; 154(6):1043-51. PubMed ID: 18035073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty.
    de Winter RJ; Heyde GS; Koch KT; Fischer J; van Straalen JP; Bax M; Schotborgh CE; Mulder KJ; Sanders GT; Piek JJ; Tijssen JG
    Eur Heart J; 2002 Jun; 23(12):960-6. PubMed ID: 12069451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
    Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
    Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.